NEWER LUNG CANCER CHEMOTHERAPY SIGNIFICANTLY MORE COSTLY THAN OLDER REGIMEN Although there is statistically no difference in survival or cancer-related quality-of-life after treatment for non-small-cell lung cancer with carboplatin plus paclitaxel or cisplatin plus vinorelbine, carboplatin plus paclitaxel therapy is significantly more expensive. Reuters Health Information 2002 MEDSCAPE Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.